New drug targets 'Undruggable' cancer mutation in major trial
Disease control
Recruiting now
This study is testing a new drug called TSN1611 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The first part aims to find the safest and most effective dose, and the second part will see how well the drug works alone or combined with …
Phase: PHASE1, PHASE2 • Sponsor: Tyligand Pharmaceuticals (Suzhou) Limited • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC